Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase

G. Meloni, P. De Fabritiis, G. Alimena, F. Malagnino, E. Montefusco, A. Sandrelli, R. Pinto, M. Vignetti, F. Lo Coco, F. Mandelli

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The progressive and fatal course of chronic myelogenous leukemia has not been affected significantly by chemotherapeutic agents that control the benign phase of the disease. Combination chemotherapy and aggressive treatments may offer some advantages: however, these approaches do not appear to produce stable suppression of Ph1 chromosome or to prolong chronic phase and survival of these patients. Only allogeneic bone marrow transplantation has been demonstrated to be capable of inducing a stable, complete suppression of Ph1+ cells. Recently alpha interferons (IFN) have been shown to control myeloid proliferation in patients with CML and to determine a progressive and persistent decline of Ph1+ bone marrow cells in some cases. The hypothesis that in most newly diagnosed patients with CML various amount of Ph1 negative cells must still be present, albeit in suppressed state in the bone marrow (BM) or in the peripheral blood (PB), have led some authors to treat patients with high-dose chemotherapy followed by reinfusion of stem cells collected at diagnosis or after a response to cytoreductive treatments. We report 34 patients with CML treated in chronic phase with Busulphan and Melphalan conditioning regimen followed by reinfusion of BM or PB stem cells.

Original languageEnglish
Pages (from-to)92-94
Number of pages3
JournalBone Marrow Transplantation
Volume4
Issue numberSUPPL. 4
Publication statusPublished - 1989

Fingerprint

Leukemia, Myeloid, Chronic Phase
Peripheral Blood Stem Cell Transplantation
Bone Marrow
Busulfan
Philadelphia Chromosome
Melphalan
Homologous Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination Drug Therapy
Bone Marrow Transplantation
Interferon-alpha
Bone Marrow Cells
Stem Cells
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Meloni, G., De Fabritiis, P., Alimena, G., Malagnino, F., Montefusco, E., Sandrelli, A., ... Mandelli, F. (1989). Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase. Bone Marrow Transplantation, 4(SUPPL. 4), 92-94.

Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase. / Meloni, G.; De Fabritiis, P.; Alimena, G.; Malagnino, F.; Montefusco, E.; Sandrelli, A.; Pinto, R.; Vignetti, M.; Lo Coco, F.; Mandelli, F.

In: Bone Marrow Transplantation, Vol. 4, No. SUPPL. 4, 1989, p. 92-94.

Research output: Contribution to journalArticle

Meloni, G, De Fabritiis, P, Alimena, G, Malagnino, F, Montefusco, E, Sandrelli, A, Pinto, R, Vignetti, M, Lo Coco, F & Mandelli, F 1989, 'Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase', Bone Marrow Transplantation, vol. 4, no. SUPPL. 4, pp. 92-94.
Meloni G, De Fabritiis P, Alimena G, Malagnino F, Montefusco E, Sandrelli A et al. Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase. Bone Marrow Transplantation. 1989;4(SUPPL. 4):92-94.
Meloni, G. ; De Fabritiis, P. ; Alimena, G. ; Malagnino, F. ; Montefusco, E. ; Sandrelli, A. ; Pinto, R. ; Vignetti, M. ; Lo Coco, F. ; Mandelli, F. / Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase. In: Bone Marrow Transplantation. 1989 ; Vol. 4, No. SUPPL. 4. pp. 92-94.
@article{8914559b2c6a4feab43808f4707a8177,
title = "Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase",
abstract = "The progressive and fatal course of chronic myelogenous leukemia has not been affected significantly by chemotherapeutic agents that control the benign phase of the disease. Combination chemotherapy and aggressive treatments may offer some advantages: however, these approaches do not appear to produce stable suppression of Ph1 chromosome or to prolong chronic phase and survival of these patients. Only allogeneic bone marrow transplantation has been demonstrated to be capable of inducing a stable, complete suppression of Ph1+ cells. Recently alpha interferons (IFN) have been shown to control myeloid proliferation in patients with CML and to determine a progressive and persistent decline of Ph1+ bone marrow cells in some cases. The hypothesis that in most newly diagnosed patients with CML various amount of Ph1 negative cells must still be present, albeit in suppressed state in the bone marrow (BM) or in the peripheral blood (PB), have led some authors to treat patients with high-dose chemotherapy followed by reinfusion of stem cells collected at diagnosis or after a response to cytoreductive treatments. We report 34 patients with CML treated in chronic phase with Busulphan and Melphalan conditioning regimen followed by reinfusion of BM or PB stem cells.",
author = "G. Meloni and {De Fabritiis}, P. and G. Alimena and F. Malagnino and E. Montefusco and A. Sandrelli and R. Pinto and M. Vignetti and {Lo Coco}, F. and F. Mandelli",
year = "1989",
language = "English",
volume = "4",
pages = "92--94",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Autologous bone marrow or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase

AU - Meloni, G.

AU - De Fabritiis, P.

AU - Alimena, G.

AU - Malagnino, F.

AU - Montefusco, E.

AU - Sandrelli, A.

AU - Pinto, R.

AU - Vignetti, M.

AU - Lo Coco, F.

AU - Mandelli, F.

PY - 1989

Y1 - 1989

N2 - The progressive and fatal course of chronic myelogenous leukemia has not been affected significantly by chemotherapeutic agents that control the benign phase of the disease. Combination chemotherapy and aggressive treatments may offer some advantages: however, these approaches do not appear to produce stable suppression of Ph1 chromosome or to prolong chronic phase and survival of these patients. Only allogeneic bone marrow transplantation has been demonstrated to be capable of inducing a stable, complete suppression of Ph1+ cells. Recently alpha interferons (IFN) have been shown to control myeloid proliferation in patients with CML and to determine a progressive and persistent decline of Ph1+ bone marrow cells in some cases. The hypothesis that in most newly diagnosed patients with CML various amount of Ph1 negative cells must still be present, albeit in suppressed state in the bone marrow (BM) or in the peripheral blood (PB), have led some authors to treat patients with high-dose chemotherapy followed by reinfusion of stem cells collected at diagnosis or after a response to cytoreductive treatments. We report 34 patients with CML treated in chronic phase with Busulphan and Melphalan conditioning regimen followed by reinfusion of BM or PB stem cells.

AB - The progressive and fatal course of chronic myelogenous leukemia has not been affected significantly by chemotherapeutic agents that control the benign phase of the disease. Combination chemotherapy and aggressive treatments may offer some advantages: however, these approaches do not appear to produce stable suppression of Ph1 chromosome or to prolong chronic phase and survival of these patients. Only allogeneic bone marrow transplantation has been demonstrated to be capable of inducing a stable, complete suppression of Ph1+ cells. Recently alpha interferons (IFN) have been shown to control myeloid proliferation in patients with CML and to determine a progressive and persistent decline of Ph1+ bone marrow cells in some cases. The hypothesis that in most newly diagnosed patients with CML various amount of Ph1 negative cells must still be present, albeit in suppressed state in the bone marrow (BM) or in the peripheral blood (PB), have led some authors to treat patients with high-dose chemotherapy followed by reinfusion of stem cells collected at diagnosis or after a response to cytoreductive treatments. We report 34 patients with CML treated in chronic phase with Busulphan and Melphalan conditioning regimen followed by reinfusion of BM or PB stem cells.

UR - http://www.scopus.com/inward/record.url?scp=0024948602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024948602&partnerID=8YFLogxK

M3 - Article

C2 - 2576389

AN - SCOPUS:0024948602

VL - 4

SP - 92

EP - 94

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL. 4

ER -